Outcomes Model Publications
Publications
Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90)
Jose Leal, Maria Alva, Vanessa Gregory, Alison Hayes, Borislava Mihaylova, Alastair M Gray, Rury R. Holman, Philip Clarke
Diabet Med. 2021;38:e14656. Published:Oct-2021. Epub:23-Jul-2021.
PMID:34297424. doi:10.1111/dme.14656
Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data
Helen A. Dakin, José Leal, Andrew Briggs, Philip Clarke, Rury R. Holman, Alastair Gray
Med Decis Making. 2020;40:460-473. Published:May-2020. Epub:20-May-2020.
PMID:32431211. doi:10.1177/0272989X20916442
UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82
Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM
Diabetologia 2013;56:1925-1933. Published:Sep-2013. Epub:22-Jun-2013.
PMID:23793713. doi:10.1007/s00125-013-2940-y
Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting
The Mount Hood 4 Modeling Group
Diabetes Care 2007;30:1638-1646. Published:Jun-2007.
PMID:17526823. doi:10.2337/dc07-9919
PROactive Study
Holman RR, Retnakaran R, Farmer A, Stevens RJ
Lancet 2006;367:25-26. Published:07-Jan-2006. Epub:05-Jan-2006.
PMID:16399144. doi:10.1016/S0140-6736(06)67914-2
Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)
Clarke PM, Gray AM, Briggs A, Stevens RJ, Matthews DR, Holman RR
Diabetologia 2004;47:1747-1759. Published:Oct-2004. Epub:27-Oct-2004.
PMID:15517152. doi:10.1007/s00125-004-1527-z
The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No 65)
Clarke P, Gray A, Legood R, Briggs A, Holman R
Diab Med. 2003;20:442-450. Published:Jun-2003. Epub:18-Jul-2003.
PMID:12786677. doi:10.1046/j.1464-5491.2003.00972.x
Estimating utility values for health states of type 2 diabetic patients using the EQ-5D
Clarke P, Gray A, Holman R
Medical Decision Making 2002;4:340-349. Published:Aug-2002.
PMID:12150599. doi:10.1177/0272989X0202200412
Conference Abstracts
Diabetes UK Annual Professional Conference, Manchester
Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
RL Coleman, A Gray, UC Broedl, D Fitchett, JT George, HJ Woerle, B Zinman and RR Holman
Diabetic Medicine 2017;34 (Suppl 1):5 - 35
[Abstract]
Diabetes UK Annual Professional Conference, Manchester
Estimating the potential incremental benefits on Type 2 diabetes complications rates of targeting successively lower LDL-cholesterol levels
SA Mostafa, RL Coleman, OF Agbaje, A Gray, RR Holman and MA Bethel
Diabetic Medicine 2017;34 (Suppl 1):36-194
[Abstract]
53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon
Risk of anaemia with long-term metformin use in a community setting
L.A. Donnelly, K. Gardner, R.L. Coleman, N. Sattar, A.T. Hattersley, R.R. Holman, E.R. Pearson
Diabetelogia 2017;60:(Suppl 1):S139
[Abstract]
52nd Annual Meeting of the European Association for the Study of Diabetes, Munich
Estimated 10-year benefit for diabetes complication rates by 1% HbA1c decrements in people with type 2 diabetes and cardiovascular disease
S.A. Mostafa, R.R. Holman, R.L. Coleman, O. Agbaje, M.A. Bethel
Diabetologia 2016;59:Suppl 1:S543